Efficacy and Safety of Submucosal Intravesical Injection of Platelet-Rich Plasma in the Treatment of Interstitial Cystitis/Painful Bladder Syndrome
International Urogynecology Journal · 2025
DOI: 10.1007/s00192-025-06324-6 ↗Kurz gefasst
Klinische Studie in der Zeitschrift International Urogynecology Journal, 2025. Verfasst von M Sherif Mourad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Faculty of Medicine , Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Cystitis, Interstitial, Platelet-Rich Plasma. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ain Shams University.
Abstract (Originalsprache)
Introduction and Hypothesis The aim of this study was to assess the effectiveness of a single session of submucosal intravesical injections of autologous platelet-rich plasma in the treatment of IC/PBS resistant to conventional methods of treatment.
Methods
This is a prospective one-arm clinical trial that was conducted from April 2021 to April 2023 on 30 patients ranging from 30 to 50 years old with Interstitial Cystitis/Painful Bladder Syndrome symptoms (IC/PBS) not relieved by medical treatment. They were assessed by the O'Leary-Sant Interstitial Cystitis Symptom Index and problem indexes (ICSI) (ICPI). They received a single session of 20 submucosal injections of PRP and were assessed after 1, 3, and 6 months.
Results
Four patients declined to show in the follow-up visits (13.3%) due to personal reasons and were excluded from the final analysis due to incomplete outcome data. Out of 26 patients, 16 patients (61.54%) were considered to have successful results, while treatment failed in 10 patients (38.46%). There was a highly statistically significant decrease in ICPI, ICSI, pain VAS score, frequency, nocturia, and functional bladder capacity (FBC) with a p value of < 0.001. Hematuria was observed in three patients (11.5%), while urinary tract infection (UTI) was detected in four patients (15.4%).
Conclusions
A single session of submucosal intravesical injections of platelet-rich plasma (PRP) presents a promising therapeutic option for patients with IC/PBS. The constrains of this research encompass the absence of a placebo arm, further randomized controlled trials are needed to prove its efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Faculty of Medicine , Ain Shams University, Cairo, Egypt.
- Department of Urology, Faculty of Medicine , Ain Shams University, Cairo, Egypt. dr_yona@med.asu.edu.eg.
ORCID-Profile: Younan R Samir
Förderung
- Ain Shams University
Zitieren
APA
Mourad, M. S., Tawfick, A., Kotb, M., Saleh, I. M., Salim, M. S., & Samir, Y. R. (2025). Efficacy and Safety of Submucosal Intravesical Injection of Platelet-Rich Plasma in the Treatment of Interstitial Cystitis/Painful Bladder Syndrome. International Urogynecology Journal. https://doi.org/10.1007/s00192-025-06324-6
Vancouver
Mourad MS, Tawfick A, Kotb M, Saleh IM, Salim MS, Samir YR. Efficacy and Safety of Submucosal Intravesical Injection of Platelet-Rich Plasma in the Treatment of Interstitial Cystitis/Painful Bladder Syndrome. International Urogynecology Journal. 2025. doi:10.1007/s00192-025-06324-6
BibTeX
@article{Mourad2025,
author = {Mourad, M Sherif and Tawfick, Ahmed and Kotb, Mohamed and Saleh, Ismail Mahdy and Salim, Mohamed S and Samir, Younan R},
title = {Efficacy and Safety of Submucosal Intravesical Injection of Platelet-Rich Plasma in the Treatment of Interstitial Cystitis/Painful Bladder Syndrome},
journal = {International Urogynecology Journal},
year = {2025},
doi = {10.1007/s00192-025-06324-6}
}
EUVIMED